Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis [1] (multiple letters)

New England Journal of Medicine

Volumn 350, Issue 2, 2004, Pages 189-192

  Vegni, Ferdinando E ^a   Corradini, Constantino ^b   Privitera, Gaetano ^a   Sugiyama, Toshihiro ^c   Tanaka, Hiroshi ^c   Kawai, Shinya ^c   Miller, Paul D ^d   Fuller, Kathleen E ^e   Black, Dennis M ^f   Bilezikian, John ^g   Rosen, Clifford J ^h   Finkelstein, Joel S ⁱ   Neer, Robert M ⁱ  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d University of Colorado Health Sciences Center   (United States)

^e AnthroHealth   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h ST JOSEPH HOSPITAL   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIFEDIOL; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; TILUDRONIC ACID; 25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN D; VITAMIN K GROUP; RECOMBINANT PROTEIN; CELL RECEPTOR; GLYCOPROTEIN; TNFRSF11B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

BONE MINERAL; BONE TURNOVER; DRUG EFFECT; HUMAN; LETTER; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; BLOOD; BONE REMODELING; DRUG COMBINATION; FEMALE; NOTE; POSTMENOPAUSE OSTEOPOROSIS; VITAMIN D DEFICIENCY; PATHOPHYSIOLOGY; BONE DENSITY; HIP FRACTURE;

ALENDRONATE; BONE REMODELING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; VITAMIN D; VITAMIN D DEFICIENCY; VITAMIN K; BONE DENSITY; HIP FRACTURES; RECOMBINANT PROTEINS; GLYCOPROTEINS; OSTEOPOROSIS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0346096737     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200401083500219     Document Type: Letter

References (0)